Stem Cell Trials Show Promise for Tinnitus and Neural Hearing Loss Treatment

By Diana Kharchenko

September 17th, 2025

BURLINGTON, ON

Researchers in multiple countries are advancing stem cell trial research aimed at repairing the inner ear to restore hearing in people with tinnitus and neural hearing loss. The initial research investigations aim to determine if cochlear hair cells, which transform sound into brain signals, can be regenerated.

The 2022 JAMA Neurology review established that tinnitus impacts 14.4% of adults worldwide, resulting in more than 740 million cases, while severe tinnitus affects 2.3% of the population (JAMA Neurology). The available treatments, including hearing aids and cochlear implants, and sound therapy, provide symptom relief, but they cannot restore typical hearing function.

Researchers at Harvard Medical School’s Mass Eye and Ear used a drug-like cocktail to stimulate hair cell regeneration in mice, which shows promise for human clinical applications.

Dr. Zheng-Yi Chen from Harvard Medical School’s Otolaryngology-Head & Neck Surgery department described hair cell regeneration in the inner ear as the ultimate goal of hearing research. The research shows that clinical applications are possible for the future (Harvard Medical School).

Advances in Regenerative Research

Tinnitus and many forms of neural hearing loss result from damage to cochlear hair cells or their neural connections. The therapy with mesenchymal stem cells (MSCs) works to establish a supportive environment for the body’s repair mechanisms by delivering growth factors and enhancing immune responses and microcirculation.

Traditional treatments, including hearing aids and cochlear implants, and medications, help millions of people, but they cannot fix the complete damage to the ear.

Dr. Chris Cunningham from the University of Pittsburgh (Eye & Ear Foundation) explained that these devices bring revolutionary life-changing benefits, yet they cannot restore normal hearing completely.

Many stem cell trial programs now focus on MSCs, adult multipotent stromal cells sourced from a patient’s tissue or donated placental and umbilical cord tissue. MSCs avoid the ethical concerns associated with embryonic stem cells and have a lower risk of immune rejection.

According to reviews in Frontiers in Cellular Neuroscience (Warnecke et al., 2021) and Molecular Biology Reports (2020), MSCs have been shown to reduce inflammation, protect nerve cells, repair synaptic connections, and promote new blood vessel growth to improve circulation.

Global and Clinical Perspectives

Scientists throughout the world continue to study cell-based hearing loss treatments in laboratories and clinics because they share a common goal of developing treatments that surpass symptom relief.

Beyond university laboratories, some private clinics are also exploring regenerative approaches for tinnitus and neural hearing loss. The European clinic Swiss Medica operates among multiple facilities that provide stem cell therapy for tinnitus through MSCs. The clinic explains that these treatments work to decrease inflammation while defending auditory nerve structures and promoting tissue regeneration.

The U.S. medical institution AdventHealth initiated a Phase I/II clinical trial to evaluate autologous umbilical cord blood infusion for treating acquired hearing loss in children while focusing on safety and practicality. The MHRA granted approval to Rinri Therapeutics in 2025 for starting human trials of Rincell-1, which functions as a regenerative cell therapy to fix damaged auditory nerves.

Scientists throughout the world continue to study cell-based hearing loss treatments in laboratories and clinics because they share a common goal of developing treatments that surpass symptom relief.

Future Outlook

While early results are encouraging, experts emphasise that stem cell therapies for hearing disorders remain experimental.

According to a systematic review in the International Journal of Otolaryngology and Head & Neck Surgery (Ganchi, 2025), stem cell therapy shows promise for potentially curing congenital hearing loss via cochlear regeneration. However, significant hurdles in protocol development, long-term efficacy, and safety must still be addressed.

Conclusion
Recent developments in stem cell trials are shifting the treatment of tinnitus and neural hearing loss toward addressing the underlying damage rather than just managing symptoms. While still in trials, these regenerative therapies could significantly change the landscape of hearing restoration.